Yuvezzi for Presbyopia

The #presbyopia landscape continues to evolve. We caught up with Carol Kearney to discuss the commercial launch of Yuvezzi and what it means for eye care professionals. In this conversation, she shares why the need for additional presbyopia treatment options remains significant, the clinical data supporting Yuvezzi, and how the therapy was designed with everyday patient use in mind. She also highlights key takeaways from the Phase III program, including duration of effect, safety, and what clinicians can expect as they begin incorporating this new option into practice. As pharmacologic treatment options continue to expand, conversations around presbyopia management are changing. It'll be interesting to see how these therapies fit alongside traditional approaches and which patients stand to benefit the most. Have you started incorporating prescription drops into your presbyopia conversations? We'd love to hear how you're approaching patient selection and counseling.